Drug Shortage Report for BEYFORTUS
Report ID | 245452 |
Drug Identification Number | 02537214 |
Brand name | BEYFORTUS |
Common or Proper name | Beyfortus |
Company Name | SANOFI PASTEUR LIMITED |
Market Status | MARKETED |
Active Ingredient(s) | NIRSEVIMAB |
Strength(s) | 100MG |
Dosage form(s) | SOLUTION |
Route of administration | INTRAMUSCULAR |
Packaging sizes (GTIN)
Click here to see a list of all reports for this drug. |
(See additional packaging sizes) |
Additional packaging sizes | 100 mg single-use, pre-filled syringe |
ATC code | J06BD |
ATC description | |
Reason for shortage | Demand increase for the drug. |
Anticipated start date | 2024-12-20 |
Actual start date | 2024-12-19 |
Estimated end date | 2025-03-30 |
Actual end date | 2025-04-07 |
Shortage status | Resolved |
Updated date | 2025-04-08 |
Company comments | Sanofi is proactively securing additional doses from our global supply to quickly respond to an increase in demand, following inquiries for more doses to address a predicted surge in provincial uptake as the RSV season is projected to peak in January. The additional volumes are pre-emptive in nature and beyond the provincial contractual commitments. |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | 1755 STEELES AVENUE WEST TORONTO, ONTARIO CANADA M2R 3T4 |
Company contact information | Customer Service/Service à la clientèle: 1-800-268-4171 Vaccine Information Service/Service d'information sur les vaccins: 416-667-2611 or 1-888-621-1146 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v9 | 2025-04-08 | English | Compare |
v8 | 2025-04-07 | French | Compare |
v7 | 2025-04-07 | English | Compare |
v6 | 2025-01-10 | French | Compare |
v5 | 2025-01-10 | English | Compare |
v4 | 2024-12-21 | English | Compare |
v3 | 2024-12-11 | French | Compare |
v2 | 2024-12-11 | English | Compare |
v1 | 2024-12-11 | English | Compare |
Showing 1 to 9 of 9